Cargando…
Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
BACKGROUND: Current guidelines lack recommendations for the use of immunotherapy and immune-related biomarkers for hepatocellular carcinoma (HCC). We aim to provide reliable evidence of the association of survival with HCC immunotherapy and to demonstrate that genomic mutation signature could be an...
Autores principales: | Ou, Qiyun, Yu, Yunfang, Li, Anlin, Chen, Jie, Yu, Tingting, Xu, Xiaolin, Xie, Xinxin, Chen, Yongjian, Lin, Dagui, Zeng, Qiaohong, Zhang, Yuxin, Tang, Xudong, Yao, Herui, Luo, Baoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154492/ https://www.ncbi.nlm.nih.gov/pubmed/32309377 http://dx.doi.org/10.21037/atm.2020.01.32 |
Ejemplares similares
-
Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants
por: Yu, Yunfang, et al.
Publicado: (2020) -
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer: A Meta-analysis and Individual Patient–Level Analysis
por: Yu, Yunfang, et al.
Publicado: (2019) -
Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation
por: He, Zifan, et al.
Publicado: (2020) -
Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
por: Yu, Yunfang, et al.
Publicado: (2020) -
Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020)